Skip to content
RKWD
ROCKWOOD RESEARCH · A CORPORATE FILINGS WEBSITE|STRAIGHT FROM THE SOURCE · SEC EDGAR|SPONSOREDYour message on this tape — bid on the Rockwood Ad Exchange · Rockwood Ad Exchange|
Rockwood Research
…

KRSA

Korsana Biosciences, Inc.

Pharmaceutical Preparations · SIC 2834CIK 1755237Held by 3 tracked managersEDGAR filings ↗10-K/10-Q ↗

SHARE:XLINKEDINEMAIL
Revenue FY2025
$2.0M
Net Income FY2025
$(4.0M)
EPS (Basic, as reported)
$-1.11
Net Margin FY2025
-170.1%
ROE FY2025
-38.8%
Total Equity
$9.0M
Shares Out
46M
Business description

Korsana Biosciences, Inc. — Pharmaceutical Preparations. Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2018–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions
i
default rows · click any row to chart itRevenue: 5 → 2 -14.2% CAGR
Revenue—5242022
Research & development(88)(95)(56)(38)(31)(2)0(1)
General & administrative(28)(34)(29)(21)(15)(8)(5)(6)
Total operating expenses(115)(130)(84)(59)(46)(13)(6)(7)
Operating income(115)(125)(81)(55)(44)(13)(4)(5)
Other income (expense), net——100011
Pre-tax income(115)(122)(78)(52)(44)(5)(3)(4)
Income tax expense00000000
Net income(115)(123)(78)(52)(44)(5)(3)(4)
EPS — basic———($1.32)($1.01)($2.25)($1.21)($1.11)
EPS — diluted———($1.32)($1.01)($2.25)($1.21)($1.11)
Shares outstanding — basic (M)———3943233
Shares outstanding — diluted (M)———3943233
  • ⚑ Weighted-average shares changed ÷20.00 between FY2022 and FY2023 — likely a reverse split. Per-share figures on either side are as reported and not adjusted.
  • ⚑ Weighted-average shares changed ×1.50 between FY2023 and FY2024 — likely a stock split. Per-share figures on either side are as reported and not adjusted.

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.